Cargando…
Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life
PURPOSE: Treatment of severe asthma has made great strides thanks to rapid progress in understanding immune response and inflammatory pathways. This led to the advent of the first biologic for severe allergic asthma (SAA), omalizumab. Although the long-term efficacy and safety of omalizumab has been...
Autores principales: | Menzella, Francesco, Fontana, Matteo, Contoli, Marco, Ruggiero, Patrizia, Galeone, Carla, Capobelli, Silvia, Simonazzi, Anna, Catellani, Chiara, Scelfo, Chiara, Castagnetti, Claudia, Livrieri, Francesco, Facciolongo, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039243/ https://www.ncbi.nlm.nih.gov/pubmed/35495876 http://dx.doi.org/10.2147/JAA.S363398 |
Ejemplares similares
-
Real world effectiveness of benralizumab on respiratory function and asthma control
por: Menzella, Francesco, et al.
Publicado: (2021) -
Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021) -
Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab
por: Menzella, Francesco, et al.
Publicado: (2021) -
Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
por: Menzella, Francesco, et al.
Publicado: (2017) -
A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM)
por: Menzella, Francesco, et al.
Publicado: (2021)